Clinical Innovations introduces traxi Panniculus Retractor with Retentus Technology

Clinical Innovations, a leading manufacturer of labor and delivery equipment, today announced the launch of traxi™ Panniculus Retractor with Retentus™ Technology. traxi lifts and retracts the dense layer of fatty tissue during abdominal procedures. When used in cesarean sections, it allows for a safer labor and delivery experience for mothers with a high BMI (body mass index).

GSquared Medical, based in Brentwood, Tenn., developed the Retentus device after their co-founder, Dr. Gregory Gapp, realized the need for a solution in the operating room to aid physicians and provide better access to the surgical site, specifically in cesarean sections. Clinical Innovations has an exclusive license to Retentus intellectual property for use in abdominal surgery from GSquared Medical.

According to the American College of Obstetricians and Gynecologists, nearly 50 percent of obese mothers with BMIs between 35 and 39.9 undergo a cesarean section. "The thick folds of skin around the abdomen, medically referred to as the panniculus, create difficulties and risks, such as imprecise incisions and infection of the surgical site for cesarean sections," said Dr. Gapp.

The quick and easy to apply traxi enhances the delivery experience for both doctors and patients by:

  • Eliminating the need for extra personnel in the operating room and allowing for greater attention to the placement and type of incision
  • Reducing the strain on surgical staff
  • Conserving operating room time, which for mothers with a high BMI can span more than two hours

"The traxi Panniculus Retractor with Retentus Technology is as perfect a solution to the pannus problem as I have ever tried," said Dr. James Greenberg, Chief, Division of Gynecology, Brigham and Women's Faulkner Hospital.

traxi Panniculus Retractor was recently featured in Contemporary OB/GYN.


Clinical Innovations


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
New study evaluates the safety profile of the BNT162b2 vaccine in New Zealand